Search
Edesa Biotech Inc
EDSAAdd to Watchlist
7.800USD
-0.150-1.89%
Market hours （ET）Quotes delayed by 15 min
65.00MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.89%
5 Days
+13.37%
1 Month
-25.43%
6 Months
+499.99%
Year to Date
+449.29%
1 Year
+290.00%
Key Figures
7.870Open
8.275High
87.10KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.05%Turnover Ratio
7.950Prev. Close
7.570Low
456.69KTurnover
LossP/E Static
13.96P/B
0.00%Div Yield TTM
-72.43%ROA
20.32052wk High
1.07Volume Ratio
-6.17MNet Profit
8.33MShares
-1.3057EPS TTM
1.11Beta
-255.48%ROE
0.72052wk Low
8.87%Amplitude
--Gross Margin
65.00MMarket Cap
-1.63Reward/Risk
11.09%Risk Rate
TradingKey Stock Score of Edesa Biotech Inc
Currency: USD Updated: 2026-06-24Key Insights
Edesa Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 388 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Edesa Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Edesa Biotech Inc Highlights
StrengthsRisks
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Undervalued
The company’s latest PE is -6.09, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.36M shares, increasing 23.32% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 1.31 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.77.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
12.000
Target Price
+63.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Edesa Biotech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Edesa Biotech Inc Info
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Ticker SymbolEDSA
CompanyEdesa Biotech Inc
CEONijhawan (Pardeep)
Websitehttps://www.edesabiotech.com/
Related Instruments
+1.73%
+2.01%
+1.57%
+3.38%
+2.83%
+1.76%
+1.28%
+1.03%
-0.11%
+0.06%
+1.53%
+1.59%
+2.43%
+1.79%
+1.05%
0.00%
+0.36%
+0.89%
+4.24%
-0.29%Popular Instruments
52284.100
+312.400 (+0.60%)
29512.500
-281.700 (-0.94%)
7383.300
-27.100 (-0.37%)
15771.000
+234.000 (+1.51%)
71583.000
+626.000 (+0.88%)
6285.200
+57.000 (+0.92%)
71.574
+1.815 (+2.60%)
277.930
-15.150 (-5.17%)
196.130
-2.870 (-1.44%)
4042.970
+44.230 (+1.11%)
FAQs
What is the current price of Edesa Biotech Inc (EDSA)?
The current price of Edesa Biotech Inc (EDSA) is 7.95.
What is the symbol of Edesa Biotech Inc?
The ticker symbol of Edesa Biotech Inc is EDSA.
What is the 52-week high of Edesa Biotech Inc?
The 52-week high of Edesa Biotech Inc is 20.32.
What is the 52-week low of Edesa Biotech Inc?
The 52-week low of Edesa Biotech Inc is 0.72.
What is the market capitalization of Edesa Biotech Inc?
The market capitalization of Edesa Biotech Inc is 70.69M.
Is Edesa Biotech Inc (EDSA) currently rated as Buy, Hold, or Sell?
According to analysts, Edesa Biotech Inc (EDSA) has an overall rating of Buy, with a price target of 12.00.
What is the Earnings Per Share (EPS TTM) of Edesa Biotech Inc (EDSA)?
The Earnings Per Share (EPS TTM) of Edesa Biotech Inc (EDSA) is -1.27.
